HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Supplement GMP Recordkeeping Estimate Fails Industry Proofread

This article was originally published in The Rose Sheet

Executive Summary

Like FDA's draft guidance on NDI notifications and its previous estimates for compliance with that regulation and the GMP final rule, the agency's latest estimate on manufacturers' annual burdens associated with GMP recordkeeping prompts industry questions.

You may also be interested in...



US FDA Keeps Estimate For NDI Notification Burden At Level Supplement Industry Doubts

FDA again sets expected costs at level supplement industry repeatedly has said drastically underestimates spending on preparing and submitting NDI notifications. But FDA says developing scientific evidence to support a notification is separate from submitting the information to the agency.

FDA Combines Supplement GMP Recordkeeping, Testing Waiver Estimates

FDA didn't change its estimates for industry's annual regulatory burden – 929,140 hours – from compliance with recordkeeping requirements in supplement GMPs, its estimates of eight hours needed to prepare a request for exemption from identity-testing requirement also in unchanged.

NDI Notification Costs Estimate, P&G Board: Health And Wellness Industry News

FDA NDI notification costs estimate unchanged; P&G proxy vote update favors Peltz; and trio of advertising violations for California supplement, skin care firms.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel